PTCT
PTC Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.90B
P/E Ratio
8.31
EPS
$8.58
Beta
0.55
52W High
$87.50
52W Low
$35.95
50-Day MA
$69.20
200-Day MA
$64.53
Dividend Yield
—
Profit Margin
39.40%
Forward P/E
55.25
PEG Ratio
0.81
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Fundamentals
| Revenue (TTM) | $1.73B |
| Gross Profit (TTM) | $1.23B |
| EBITDA | $895.32M |
| Operating Margin | -49.60% |
| Return on Equity | -7740.00% |
| Return on Assets | 23.30% |
| Revenue/Share (TTM) | $21.76 |
| Book Value | $-2.52 |
| Price-to-Book | 1743.27 |
| Price-to-Sales (TTM) | 3.41 |
| EV/Revenue | 3.682 |
| EV/EBITDA | 7.18 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -22.70% |
| Shares Outstanding | $82.78M |
| Float | $72.94M |
| % Insiders | 7.44% |
| % Institutions | 113.45% |
Analyst Ratings
Consensus ($86.50 target)
3
Strong Buy5
Buy5
Hold1
SellData last updated: 4/9/2026